Treatment of macular degeneration from MacuCLEAR
MacuCLEAR will grow through strategic alliances, consistent with the industry trend of large pharmaceutical and biotech companies seeking novel drugs to fill their product pipelines and diminishing intellectual property portfolios. The company intends to out-license its portfolio of novel drug formulations for various ophthalmic diseases and will derive income from licensing fees, milestone payments and royalties.
MacuCLEAR is currently raising $6M in Series A-1 Preferred Stock which will be used for its Phase II/III Human Clinical Study. Stock Purchase details are available through the "Contact Us" page.